Gene therapy is ready to become hereditary

Human genetic material is stored at a laboratory in Munich May 23, 2011. On May 25, 2011 the ethic commission of the German lower house of parliament (Bundestag) will discuss about alternative proposals for a new law on the use of preimplantation genetic diagnosis (PGD). Preimplantation genetic diagnosis (Praeimplantationsdiagnostik) is a technique used to identify genetic defects in embryos created through in vitro fertilization (IVF) before pregnancy, which is banned by German legislation. REUTERS/Michael Dalder (GERMANY - Tags: POLITICS HEALTH SOCIETY SCI TECH) - RTR2MSAV

NEW YORK (Reuters Breakingviews) - Gene therapy is about ready to be the next big thing. The prospect of treating diseases by tinkering with DNA has a long history of both promise and frustration. Steady progress means 2017 should be the year the technology finally hits the U.S. market. The problem may be figuring out how to pay for cures.

In the 1990s, researchers used viruses to replace defective genetic code, essentially healing an immune-system disease. The resulting boom was short-lived, however. A death and several cases of cancer in subsequent trials ended most of the related research.

Scientists who stuck around in the field have made advances. Infective agents used today are less likely to insert their payload into a location that causes cancer, and are more likely to successfully modify targeted cells.

Two or more gene therapies soon could be approved in the United States. GlaxoSmithKline’s treatment for a rare and deadly immune disease probably will get the green light from regulators on the strength of the data. Smaller biotech Spark Therapeutics also will seek signoff for a therapy to restore vision in an inherited form of progressive blindness.

Neither may generate bountiful cash. GSK estimates there are perhaps 12 new American patients for its drug each year. It charges about 600,000 euros per person in Europe, where it already has been approved. The $90 billion pharmaceutical company hopes, however, to use its viruses, factories and know-how to roll out a different new treatment annually.

Spark’s bigger promise is in hemophilia. Subsequent potential cures could be blockbusters. Sickle-cell disease, for example, can cut decades off a patient’s life, but may be amenable to a cure. It afflicts 100,000 Americans.

These genetic developments are also having an effect in bigger diseases. One of the hottest areas in oncology is modifying immune cells to recognize cancerous ones. Regenerating damaged tissue offers even bigger, more distant prizes.

They won’t come cheaply. The industry initially thought most one-shot cures would be priced at $1 million apiece. Given that hundreds could be developed, the resulting sums would be prohibitive for many societies. Payment for therapies based on efficacy and evidence of savings elsewhere, such as reduced hospitalization, may offer a way to solve the conundrum. These genetic problems could be passed down starting next year.


Reuters Breakingviews is the world's leading source of agenda-setting financial insight. As the Reuters brand for financial commentary, we dissect the big business and economic stories as they break around the world every day. A global team of about 30 correspondents in New York, London, Hong Kong and other major cities provides expert analysis in real time.

Sign up for a free trial of our full service at and follow us on Twitter @Breakingviews and at All opinions expressed are those of the authors.